These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18827606)

  • 1. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.
    Bepler G; Sommers KE; Cantor A; Li X; Sharma A; Williams C; Chiappori A; Haura E; Antonia S; Tanvetyanon T; Simon G; Obasaju C; Robinson LA
    J Thorac Oncol; 2008 Oct; 3(10):1112-8. PubMed ID: 18827606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
    Grønberg BH; Lund-Iversen M; Strøm EH; Brustugun OT; Scott H
    J Thorac Oncol; 2013 Oct; 8(10):1255-64. PubMed ID: 24457236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach.
    De Pas TM; Toffalorio F; Giovannetti E; Radice D; Russo F; Angeli I; Calamai G; Spitaleri G; Catania C; Noberasco C; Milani A; Pelosi G; Danesi R; De Braud F
    J Thorac Oncol; 2011 Apr; 6(4):768-73. PubMed ID: 21336182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.
    Sun JM; Ahn JS; Jung SH; Sun J; Ha SY; Han J; Park K; Ahn MJ
    J Clin Oncol; 2015 Aug; 33(22):2450-6. PubMed ID: 26124486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
    Papadaki C; Sfakianaki M; Lagoudaki E; Giagkas G; Ioannidis G; Trypaki M; Tsakalaki E; Voutsina A; Koutsopoulos A; Mavroudis D; Georgoulias V; Souglakos J
    Br J Cancer; 2014 Oct; 111(9):1757-64. PubMed ID: 25233397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
    Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
    J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
    Rosell R; Felip E; Taron M; Majo J; Mendez P; Sanchez-Ronco M; Queralt C; Sanchez JJ; Maestre J
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.
    Adjei AA; Salavaggione OE; Mandrekar SJ; Dy GK; Ziegler KL; Endo C; Molina JR; Schild SE; Adjei AA
    J Thorac Oncol; 2010 Sep; 5(9):1346-53. PubMed ID: 20651609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
    Hu X; Jiao S; Zhang S; Wang Z; Wang M; Huang C; Zheng R; Li K; Wang J; Wang Y; Ouyang X; Lv W; Cheng G; Hu C; Luo R; Sun Y
    Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):569-75. PubMed ID: 23075680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
    Treat J; Bonomi P; McCleod M; Christiansen NP; Mintzer DM; Monberg MJ; Ye Z; Chen R; Obasaju CK
    Lung Cancer; 2006 Jul; 53(1):77-83. PubMed ID: 16730854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
    Dong S; Guo AL; Chen ZH; Wang Z; Zhang XC; Huang Y; Xie Z; Yan HH; Cheng H; Wu YL
    J Hematol Oncol; 2010 Mar; 3():10. PubMed ID: 20226083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
    Gridelli C; Rossi A; Di Maio M; Leo S; Filipazzi V; Favaretto AG; Burgio MA; Cinieri S; Bianco R; Ciardiello F; Cavanna L; Bordonaro R; Costanzo R; Sandomenico C; Gallo C; Perrone F; Morabito A
    Clin Lung Cancer; 2014 Mar; 15(2):166-70. PubMed ID: 24418693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
    Syrigos KN; Vansteenkiste J; Parikh P; von Pawel J; Manegold C; Martins RG; Simms L; Sugarman KP; Visseren-Grul C; Scagliotti GV
    Ann Oncol; 2010 Mar; 21(3):556-561. PubMed ID: 19828561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
    He YW; Zhao ML; Yang XY; Zeng J; Deng QH; He JX
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):861-7. PubMed ID: 25732635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
    Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
    J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
    Yang CH; Simms L; Park K; Lee JS; Scagliotti G; Orlando M
    J Thorac Oncol; 2010 May; 5(5):688-95. PubMed ID: 20150825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
    Spigel DR; Hainsworth JD; Barton JH; Patton JF; Zubkus JD; Simons L; Griner P; Burris HA; Greco FA
    J Thorac Oncol; 2010 Jun; 5(6):841-5. PubMed ID: 20421819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
    Ortuzar W; Hanna N; Pennella E; Peng G; Langer C; Monberg M; Scagliotti G
    Clin Lung Cancer; 2012 Jan; 13(1):24-30. PubMed ID: 21831719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
    Lv C; Ma Y; Feng Q; Fang F; Bai H; Zhao B; Yan S; Wu N; Zheng Q; Li S; Chen J; Wang J; Feng Y; Wang Y; Pei Y; Fang J; Yang Y
    World J Surg Oncol; 2013 Apr; 11():96. PubMed ID: 23621919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.